API | teplizumab

teplizumab Report issue

Biologics mAb Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

AACT ChEMBL MeSH

Active Ingredient History

NOW

Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

teplizumab

None

More Chemistry

Pharmacology

Mechanisms of Action:
- T-cell surface glycoprotein CD3 epsilon chain (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (22)

Research & Development (22)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Arthritis, Psoriatic (Phase 2)

Autoimmune Diseases (Phase 2)

Diabetes Mellitus, Experimental (Phase 1/Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Glucose Intolerance (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypoglycemia (Phase 1/Phase 2)

Islets of Langerhans Transplantation (Phase 1/Phase 2)

Melanoma (Phase 1)

Psoriasis (Phase 1/Phase 2)

Transplantation, Homologous (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 22

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue